[HTML][HTML] Analysis of the Association between CIMP and BRAFV600E in Colorectal Cancer by DNA Methylation Profiling
PloS one, 2009•journals.plos.org
A CpG island methylator phenotype (CIMP) is displayed by a distinct subset of colorectal
cancers with a high frequency of DNA hypermethylation in a specific group of CpG islands.
Recent studies have shown that an activating mutation of BRAF (BRAFV600E) is tightly
associated with CIMP, raising the question of whether BRAFV600E plays a causal role in the
development of CIMP or whether CIMP provides a favorable environment for the acquisition
of BRAFV600E. We employed Illumina GoldenGate DNA methylation technology, which …
cancers with a high frequency of DNA hypermethylation in a specific group of CpG islands.
Recent studies have shown that an activating mutation of BRAF (BRAFV600E) is tightly
associated with CIMP, raising the question of whether BRAFV600E plays a causal role in the
development of CIMP or whether CIMP provides a favorable environment for the acquisition
of BRAFV600E. We employed Illumina GoldenGate DNA methylation technology, which …
A CpG island methylator phenotype (CIMP) is displayed by a distinct subset of colorectal cancers with a high frequency of DNA hypermethylation in a specific group of CpG islands. Recent studies have shown that an activating mutation of BRAF (BRAFV600E) is tightly associated with CIMP, raising the question of whether BRAFV600E plays a causal role in the development of CIMP or whether CIMP provides a favorable environment for the acquisition of BRAFV600E. We employed Illumina GoldenGate DNA methylation technology, which interrogates 1,505 CpG sites in 807 different genes, to further study this association. We first examined whether expression of BRAFV600E causes DNA hypermethylation by stably expressing BRAFV600E in the CIMP-negative, BRAF wild-type COLO 320DM colorectal cancer cell line. We determined 100 CIMP-associated CpG sites and examined changes in DNA methylation in eight stably transfected clones over multiple passages. We found that BRAFV600E is not sufficient to induce CIMP in our system. Secondly, considering the alternative possibility, we identified genes whose DNA hypermethylation was closely linked to BRAFV600E and CIMP in 235 primary colorectal tumors. Interestingly, genes that showed the most significant link include those that mediate various signaling pathways implicated in colorectal tumorigenesis, such as BMP3 and BMP6 (BMP signaling), EPHA3, KIT, and FLT1 (receptor tyrosine kinases) and SMO (Hedgehog signaling). Furthermore, we identified CIMP-dependent DNA hypermethylation of IGFBP7, which has been shown to mediate BRAFV600E-induced cellular senescence and apoptosis. Promoter DNA hypermethylation of IGFBP7 was associated with silencing of the gene. CIMP-specific inactivation of BRAFV600E-induced senescence and apoptosis pathways by IGFBP7 DNA hypermethylation might create a favorable context for the acquisition of BRAFV600E in CIMP+ colorectal cancer. Our data will be useful for future investigations toward understanding CIMP in colorectal cancer and gaining insights into the role of aberrant DNA hypermethylation in colorectal tumorigenesis.
PLOS